Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3624425

N#Cc1cc(-c2ccnc(-c3cnc(N4CCCCC4)nc3)c2)[nH]c1N1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 10/20 0.37
CDC7 O00311 1/20 0.37
PIM1 P11309 1/20 0.37
CDK9 P50750 1/20 0.37
PRKD1 Q15139 2/20 0.36
PRKD2 Q9BZL6 2/20 0.36
PRKD3 O94806 1/20 0.36
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
RET P07949 1/20 0.34
MAPKAPK2 P49137 1/20 0.33
MAPT P10636 1/20 0.33
KISS1R Q969F8 1/20 0.33
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3618173 1.00 IRAK4 (0.37) IRAK4CDC7PIM1CDK9PRKD1
Trifluoroacetic Acid SCHEMBL3619396 0.99 IRAK4 (0.38) IRAK4CDC7PIM1CDK9PRKD1
Trifluoroacetic Acid SCHEMBL3613213 0.92 TBK1 (0.36) IRAK4CDC7PIM1CDK9HRH4
Trifluoroacetic Acid SCHEMBL3618387 0.92 CDC7 (0.38) IRAK4CDC7PIM1CDK9MAPT
SCHEMBL13408193 0.91 PIM1 (0.42) IRAK4CDC7PIM1CDK9PRKD1
SCHEMBL13408197 0.91 PIM1 (0.42) IRAK4CDC7PIM1CDK9PRKD1
SCHEMBL13408196 0.91 PIM1 (0.43) IRAK4CDC7PIM1CDK9PRKD1
Trifluoroacetic Acid SCHEMBL3610696 0.90 IRAK4 (0.42) IRAK4CDC7PIM1CDK9PRKD1
Trifluoroacetic Acid SCHEMBL3614800 0.88 IRAK4 (0.34) IRAK4CDC7PIM1CDK9HRH4
Trifluoroacetic Acid SCHEMBL3620819 0.87 CDK9 (0.41) IRAK4CDC7PIM1CDK9PRKD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US claimed
US-20100105664-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-04-29 US disclosed
EP-2069333-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES Novartis Ag (CH) 2009-06-17 EP disclosed
WO-2008034600-A1 PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES NOVARTIS AG (CH) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105664-A1 ORGANIC COMPOUNDS SLCO1B3, SLCO1B1, SLC10A6 IRAK4 3656/4885CDC7 4089/4885PIM1 837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.